Developer docs
API playgroundTry for free, no card

Search company profiles

OutSee

Full company profile

uuid0002b7h

Namestring
OutSee
Legal namestring
OutSee Limited
Websiteurl
outsee.co.uk
Company typeenum
Private
Founded yearint
2022
Descriptiontext

OutSee Limited is a Cambridge, UK-based computational genomics company founded in 2022 that builds AI-driven methods for therapeutic target identification and precision medicine. Its core product is Nomaly, a proprietary AI engine that predicts disease and phenotype directly from a single genome ab initio by reasoning from molecular and cell biology fundamentals rather than pattern-matching known genetic associations. The platform is positioned to complement rather than replace existing genomic methods, with claimed advantages in extracting signal from small or complex cohorts, multi-variant effects, and mechanistically cooperative genetic interactions that confound traditional association-based approaches. OutSee initially targets pharmaceutical and biotech customers developing therapeutics in CNS disorders, rare diseases, and metabolic conditions, with ALS added in 2026 via the Longitude Prize on ALS Discovery Award.

OutSee operates a B2B, partnership-driven business model. Revenue is generated through strategic collaborations, co-development agreements, and licensing arrangements with pharma, biotech, and preclinical CROs. The company's most significant commercial relationship to date is a January 2026 strategic collaboration with o2h discovery to build a library of drug candidates against OutSee's lead AI-identified therapeutic target, funded by o2h through its InflexionRx program. OutSee is also advancing non-commercial work through a research collaboration with Dr Martin Turner's group at the University of Oxford under the Longitude Prize on ALS.

The company has raised approximately £4.4M across two seed rounds (£1.8M in June 2025 and £2.5M in January 2026, both led by Ahren Innovation Capital) plus a £100,000 Discovery Award from the Longitude Prize on ALS in May 2026. It is led by founder and CEO Julian Gough and operates with a 1-10 person team. As of the latest available data, OutSee is private, has no disclosed revenue, and has not announced any acquired customers beyond its named partners.

Short descriptiontext

OutSee is a Cambridge-based AI genomics company whose Nomaly platform predicts disease and identifies therapeutic targets directly from genomic data, serving pharmaceutical and biotech partners pursuing CNS, rare, metabolic, and ALS drug discovery programs through co-development and licensing collaborations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomics drug discovery, therapeutic target identification, predictive genomics platform, AI drug discovery, precision medicine genomics
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
SIC code2 codes
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Prepackaged Software7372
Product category
AI-powered genomics drug discovery software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic partnerships and collaborations
TypeLicensing Royalties
Description

OutSee generates revenue through strategic partnerships with pharmaceutical and biotech companies, including collaborative drug discovery programs and co-development agreements where partners fund research activities.

technologynetworks.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Nomaly
Description

AI-powered predictive genomics engine that predicts disease and phenotype directly from a single genome ab initio, using fundamental molecular and cell biology rather than pattern-matching known genetic associations.

outsee.co.uk
Core offering1 text field

OutSee develops Nomaly, a predictive AI engine that predicts disease and phenotype directly from a single genome ab initio, enabling pharmaceutical and biotech partners to identify therapeutic targets and build drug candidate libraries. The platform works on small and large datasets, common and rare variation, and is initially applied to CNS disorders, rare diseases, and metabolic conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Successfully identified lead AI-identified target candidates for validation
Product overview1 text field

OutSee is a genomics and drug discovery company that offers a single unified AI platform called Nomaly. This platform serves as the core technology for predictive genomics and drug target discovery. OutSee also provides drug discovery services to partners, using the Nomaly platform to identify therapeutic targets and build libraries of drug candidates for pharmaceutical and biotech collaborations.

Product and service1 record
1Nomaly
CategoryAI drug discovery platform
Description

Nomaly is OutSee's AI engine that predicts disease and phenotype directly from a single genome ab initio. Rather than pattern-matching known genetic associations, it uncovers underlying biological mechanisms that drive and modulate disease using fundamental molecular and cell biology, working on small and large datasets, common and rare variation, and common and rare diseases. It is offered to pharmaceutical and biotech partners for therapeutic target discovery, precision medicine patient grouping, and analysis of smaller cohorts.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

OutSee selected for Discovery Award providing £100,000 funding and access to genomic data from 9,000 ALS patients. OutSee will analyze this data using its Nomaly platform over nine months to identify new therapeutic targets for ALS treatment as part of a competitive £7.5 million global challenge prize.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Research partnership with Dr Martin Turner's group at the University of Oxford as part of the Longitude Prize on ALS Discovery Award program to analyze genomic data and identify therapeutic targets for ALS.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Strategic collaboration agreement for joint drug discovery program focused on OutSee's lead AI-identified target candidate. o2h discovery, a preclinical CRO, will fund the collaboration through its InflexionRx partnership program and help build a library of drug candidates for OutSee's lead target using OutSee's Nomaly platform.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company using high-throughput biology and ML to identify novel targets and advance programs through preclinical and clinical stages. Closely comparable business model (AI for target ID and early discovery) targeting similar pharma and biotech customers.

TypeEmerging player
Description

Cambridge, UK-based clinical genomics and bioinformatics company providing genomic data analysis for rare disease and precision medicine. UK regional peer applying AI/bioinformatics to genomic interpretation, adjacent to OutSee's genomics-led discovery use cases.

TypeBroad incumbent
Description

Established computational chemistry and predictive analytics platform serving pharma with molecular simulation, predictive modeling, and discovery software. A broader incumbent offering computational drug discovery tooling overlapping with OutSee's predictive AI positioning.

TypeDirect peer
Description

London-headquartered AI drug discovery company that combines biomedical knowledge graphs and machine learning to identify new therapeutic targets. Directly comparable to OutSee as a UK-based AI target-discovery platform selling into pharma partnerships, though at a more mature stage.

5Isomorphic Labs
TypeDirect peer
Description

Alphabet-founded AI drug discovery company applying DeepMind's protein structure and generative biology models to pharma partnerships. A direct competitor in AI-driven target and drug discovery with substantially more capital and pharma deals.

TypeDirect peer
Description

Oxford-based AI drug discovery company using AI platforms to design and develop new medicines with pharma partners. Strong UK peer with similar pharma partnership GTM and AI-first discovery approach.

TypeEmerging player
Description

Cambridge-based bioinformatics platform company applying AI and network science to microbiome and multi-omics data for life sciences R&D. UK peer offering life science informatics and analytics, adjacent to OutSee's multi-omics and target discovery positioning.

TypeDirect peer
Description

Machine learning-driven drug discovery company combining induced pluripotent stem cell biology with ML to discover targets and develop therapeutics. Comparable in building predictive AI/ML platforms for pharmaceutical R&D and forming pharma partnerships.

TypeRegional player
Description

UK-based genomics data and analytics company applying population-scale genetic insights to drug target discovery and precision medicine. Comparable in genomics-led target identification from UK, though more focused on data analytics than a discovery engine.

TypeEmerging player
Description

UK-based ML-driven drug discovery company focused on using machine learning on genetic and phenotypic data to identify novel therapeutic targets. Highly comparable in approach (genetics-first AI target discovery) and stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OutSee

AI-powered genomics drug discovery softwareoutsee.co.uk

OutSee is a Cambridge-based AI genomics company whose Nomaly platform predicts disease and identifies therapeutic targets directly from genomic data, serving pharmaceutical and biotech partners pursuing CNS, rare, metabolic, and ALS drug discovery programs through co-development and licensing collaborations.

What OutSee does

OutSee Limited is a Cambridge, UK-based computational genomics company founded in 2022 that builds AI-driven methods for therapeutic target identification and precision medicine. Its core product is Nomaly, a proprietary AI engine that predicts disease and phenotype directly from a single genome ab initio by reasoning from molecular and cell biology fundamentals rather than pattern-matching known genetic associations. The platform is positioned to complement rather than replace existing genomic methods, with claimed advantages in extracting signal from small or complex cohorts, multi-variant effects, and mechanistically cooperative genetic interactions that confound traditional association-based approaches. OutSee initially targets pharmaceutical and biotech customers developing therapeutics in CNS disorders, rare diseases, and metabolic conditions, with ALS added in 2026 via the Longitude Prize on ALS Discovery Award.

OutSee operates a B2B, partnership-driven business model. Revenue is generated through strategic collaborations, co-development agreements, and licensing arrangements with pharma, biotech, and preclinical CROs. The company's most significant commercial relationship to date is a January 2026 strategic collaboration with o2h discovery to build a library of drug candidates against OutSee's lead AI-identified therapeutic target, funded by o2h through its InflexionRx program. OutSee is also advancing non-commercial work through a research collaboration with Dr Martin Turner's group at the University of Oxford under the Longitude Prize on ALS.

The company has raised approximately £4.4M across two seed rounds (£1.8M in June 2025 and £2.5M in January 2026, both led by Ahren Innovation Capital) plus a £100,000 Discovery Award from the Longitude Prize on ALS in May 2026. It is led by founder and CEO Julian Gough and operates with a 1-10 person team. As of the latest available data, OutSee is private, has no disclosed revenue, and has not announced any acquired customers beyond its named partners.

OutSee firmographics

Firmographics
Name
OutSee
Legal name
OutSee Limited
Website
https://outsee.co.uk
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
OutSee is a Cambridge-based AI genomics company whose Nomaly platform predicts disease and identifies therapeutic targets directly from genomic data, serving pharmaceutical and biotech partners pursuing CNS, rare, metabolic, and ALS drug discovery programs through co-development and licensing collaborations.
Ownership category
akta.pro rank

OutSee industry classification

Industry
Product category
AI-powered genomics drug discovery software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
SIC
Services-Computer Programming, Data Processing, Etc. (7370), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Keywords

  • Genomics drug discovery
  • Therapeutic target identification
  • Predictive genomics platform
  • AI drug discovery
  • Precision medicine genomics

Where OutSee is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

OutSee business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Strategic partnerships and collaborations: OutSee generates revenue through strategic partnerships with pharmaceutical and biotech companies, including collaborative drug discovery programs and co-development agreements where partners fund research activities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

OutSee product offering

Product offering

Core offering

OutSee develops Nomaly, a predictive AI engine that predicts disease and phenotype directly from a single genome ab initio, enabling pharmaceutical and biotech partners to identify therapeutic targets and build drug candidate libraries. The platform works on small and large datasets, common and rare variation, and is initially applied to CNS disorders, rare diseases, and metabolic conditions.

Product overview

OutSee is a genomics and drug discovery company that offers a single unified AI platform called Nomaly. This platform serves as the core technology for predictive genomics and drug target discovery. OutSee also provides drug discovery services to partners, using the Nomaly platform to identify therapeutic targets and build libraries of drug candidates for pharmaceutical and biotech collaborations.

Differentiator

Problem solved

Functional benefit

Brands

  • Nomaly: AI-powered predictive genomics engine that predicts disease and phenotype directly from a single genome ab initio, using fundamental molecular and cell biology rather than pattern-matching known genetic associations.

Products and services

  • Nomaly Nomaly is OutSee's AI engine that predicts disease and phenotype directly from a single genome ab initio. Rather than pattern-matching known genetic associations, it uncovers underlying biological mechanisms that drive and modulate disease using fundamental molecular and cell biology, working on small and large datasets, common and rare variation, and common and rare diseases. It is offered to pharmaceutical and biotech partners for therapeutic target discovery, precision medicine patient grouping, and analysis of smaller cohorts.

Quantifiable outcome

  • Successfully identified lead AI-identified target candidates for validation

Companies that use OutSee

Customer profile

Segments4 records

Ideal customer profiles1 record

OutSee technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature1 record

OutSee partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Longitude Prize on ALScoreStrategic or Co-development Partner · 1 May 2026OutSee selected for Discovery Award providing £100,000 funding and access to genomic data from 9,000 ALS patients. OutSee will analyze this data using its Nomaly platform over nine months to identify new therapeutic targets for ALS treatment as part of a competitive £7.5 million global challenge prize.
  • University of Oxford (Dr Martin Turner's group)coreStrategic or Co-development Partner · 1 May 2026Research partnership with Dr Martin Turner's group at the University of Oxford as part of the Longitude Prize on ALS Discovery Award program to analyze genomic data and identify therapeutic targets for ALS.
  • o2h discoverycoreStrategic or Co-development Partner · 1 January 2026Strategic collaboration agreement for joint drug discovery program focused on OutSee's lead AI-identified target candidate. o2h discovery, a preclinical CRO, will fund the collaboration through its InflexionRx partnership program and help build a library of drug candidates for OutSee's lead target using OutSee's Nomaly platform.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

OutSee competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-driven drug discovery company using high-throughput biology and ML to identify novel targets and advance programs through preclinical and clinical stages. Closely comparable business model (AI for target ID and early discovery) targeting similar pharma and biotech customers.
  • BenevolentAI: London-headquartered AI drug discovery company that combines biomedical knowledge graphs and machine learning to identify new therapeutic targets. Directly comparable to OutSee as a UK-based AI target-discovery platform selling into pharma partnerships, though at a more mature stage.
  • Isomorphic Labs: Alphabet-founded AI drug discovery company applying DeepMind's protein structure and generative biology models to pharma partnerships. A direct competitor in AI-driven target and drug discovery with substantially more capital and pharma deals.
  • Exscientia: Oxford-based AI drug discovery company using AI platforms to design and develop new medicines with pharma partners. Strong UK peer with similar pharma partnership GTM and AI-first discovery approach.
  • Insitro: Machine learning-driven drug discovery company combining induced pluripotent stem cell biology with ML to discover targets and develop therapeutics. Comparable in building predictive AI/ML platforms for pharmaceutical R&D and forming pharma partnerships.

Emerging players

  • Congenica: Cambridge, UK-based clinical genomics and bioinformatics company providing genomic data analysis for rare disease and precision medicine. UK regional peer applying AI/bioinformatics to genomic interpretation, adjacent to OutSee's genomics-led discovery use cases.
  • Eagle Genomics: Cambridge-based bioinformatics platform company applying AI and network science to microbiome and multi-omics data for life sciences R&D. UK peer offering life science informatics and analytics, adjacent to OutSee's multi-omics and target discovery positioning.
  • Relation Therapeutics: UK-based ML-driven drug discovery company focused on using machine learning on genetic and phenotypic data to identify novel therapeutic targets. Highly comparable in approach (genetics-first AI target discovery) and stage.

Broad incumbents

  • Schrödinger: Established computational chemistry and predictive analytics platform serving pharma with molecular simulation, predictive modeling, and discovery software. A broader incumbent offering computational drug discovery tooling overlapping with OutSee's predictive AI positioning.

Regional players

  • Genomics PLC: UK-based genomics data and analytics company applying population-scale genetic insights to drug target discovery and precision medicine. Comparable in genomics-led target identification from UK, though more focused on data analytics than a discovery engine.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

OutSee social profiles

Digital presence

OutSee financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OutSee leadership team

Management profile

Number of profiles

Profiles1 record

OutSee funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OutSee M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OutSee

What does OutSee do?

OutSee develops Nomaly, a predictive AI engine that predicts disease and phenotype directly from a single genome ab initio, enabling pharmaceutical and biotech partners to identify therapeutic targets and build drug candidate libraries. The platform works on small and large datasets, common and rare variation, and is initially applied to CNS disorders, rare diseases, and metabolic conditions.

Is OutSee a public or private company?

OutSee is a private company. It is classified as venture growth investor backed and is currently operating.

When was OutSee founded?

OutSee was founded in 2022. It employs 1 to 10 people.

Where is OutSee based?

OutSee is headquartered in Cambridge, United Kingdom, in the Europe region.

How does OutSee make money?

One revenue line is on record: strategic partnerships and collaborations.

Who are OutSee's main competitors?

Direct peers on record are Recursion Pharmaceuticals, BenevolentAI, Isomorphic Labs, Exscientia and Insitro. Emerging players are Congenica, Eagle Genomics and Relation Therapeutics. Schrödinger is listed as a broad incumbent. Genomics PLC is listed as a regional player.

Does OutSee have an API?

No public API is recorded for OutSee.

What industry is OutSee in?

OutSee's product category is AI-powered genomics drug discovery software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalOutSee awarded Innovate UK grant for agentic AI pilot study to enhance drug target validationOutSee received a £50,000 Innovate UK grant to develop an agentic AI sub-system for pilot testing its Nomaly drug target validation pipeline. The system will automate initial triage of targets, removing a manual bottleneck and accelerating validation. The company plans to share results from the study.Drug Target ReviewOutSee secures £50k innovate UK grant for AI target validationOutSee secured £50,000 from Innovate UK's Investor Partnership Grant to pilot an agentic AI sub-system for automating early-stage triage of drug targets from its Nomaly platform. The system will provide initial assessment of targets, allowing scientists to focus on detailed validation. The pilot aims to scale the validation pipeline and accelerate discovery of novel targets.AlsnewstodayOutsee wins award to support AI search for ALS treatmentsOutsee has been selected for a Discovery Award from the Longitude Prize on ALS, receiving £100,000 (about $134,000) in funding and access to genomic data from 9,000 ALS patients. The company will use its AI-powered Nomaly platform to analyze this data and identify new therapeutic targets for ALS treatment. This is the first stage of a five-year, multi-stage competition worth up to £7.5 million.Business Wire BlogOutSee Selected for Discovery Award from Longitude Prize on ALS to Accelerate AI-Based Target DiscoveryOutSee, a Cambridge-based genomics and drug discovery company, has been selected to receive a Discovery Award from the Longitude Prize on ALS, granting access to genomic data from 9,000 ALS patients and £100k in funding. The award is part of a competitive £7.5 million global challenge prize aimed at leveraging AI-based discovery to uncover new therapeutic targets for ALS, a fatal neurodegenerative disease affecting approximately 1 in 300 people. OutSee will use its proprietary AI platform, Nomaly, to analyse the dataset over nine months in partnership with researchers including Dr Martin Turner's group at the University of Oxford.BioSpaceOutSee Selected for Discovery Award from Longitude Prize on ALS to Accelerate AI-Based Target DiscoveryOutSee was selected for a Longitude Prize Discovery Award on ALS, gaining access to genomic data from 9,000 ALS patients and £100k in funding. The award supports a nine-month project using its AI platform Nomaly to identify novel therapeutic targets. The prize is part of a £7.5M global challenge to advance ALS treatment.Technology NetworksOutSee Closes £2.5M Seed To Advance AI-driven GenomicsOutSee announced the closing of a £2.5 million seed funding round and signed a strategic agreement with o2h discovery to collaborate on drug discovery programs using OutSee's Nomaly platform. The partnership will focus on building a library of drug candidates for OutSee’s lead target, leveraging AI-driven genomic target discovery. The funding aims to expand OutSee's research and development efforts and advance its proprietary technology.AI InsiderOutSee Raises £2.5M Seed and Partners With o2h Discovery to Advance AI-Driven Drug Target DevelopmentOutSee, a genomics and drug discovery company, has closed a £2.5 million seed funding round and signed a strategic collaboration with preclinical CRO o2h discovery to advance a joint drug discovery programme focused on OutSee's lead AI-identified target candidate. The seed round was led by Ahren Innovation Capital with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 angel investors, completing a first close announced in June 2025. The funding will support experimental validation of multiple AI-identified targets and continued development of OutSee's Nomaly precision medicine platform.FinSMEsOutSee Closes £2.5M Seed Funding RoundOutSee, a Cambridge-based AI genomics company, closed a £2.5 million seed funding round led by Ahren Innovation Capital with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 angel investors. The company will use the funds to advance therapeutic targets through experimental validation, build an internal asset pipeline, and enhance its Nomaly platform, which uses AI-powered predictive modeling to identify disease mechanisms directly from genomic data. OutSee has also signed a strategic agreement with o2h discovery to launch a collaborative drug discovery program.News-MedicalOutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidateOutSee, a genomics and drug discovery company, has closed a £2.5 million seed funding round led by Ahren Innovation Capital with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 angel investors. The company has simultaneously established a strategic partnership with o2h discovery, a preclinical contract research organization, to launch a collaborative drug discovery program for OutSee's lead target candidate using its AI-powered Nomaly platform. The partnership is supported by o2h's co-discovery InflexionRx match funding model covering proof-of-concept studies at the HIT ID Phase.Pulse 2.0OutSee: £2.5 Million Seed Round Completed And Partnership With o2h DiscoveryOutSee, an AI-enabled genomics and drug discovery company, has closed a £2.5 million oversubscribed seed funding round led by Ahren Innovation Capital, with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 angel investors. The company simultaneously signed a strategic partnership with o2h discovery to launch its first collaborative drug discovery programme, combining OutSee's precision medicine platform Nomaly with o2h's integrated preclinical discovery platform. The funding will support experimental validation of targets generated by Nomaly and the buildout of an internal asset pipeline.